Bone and calcium homeostasis pathways

Bone and calcium homeostasis pathways represent a complex physiological system that maintains extracellular calcium concentrations within a tight physiological range while preserving the structural integrity of the skeleton (StatPearls, 2023). This regulation is achieved through a coordinated feedback loop involving the parathyroid glands, kidneys, bone, and intestines, primarily mediated by parathyroid hormone (PTH), calcitriol (1,25-dihydroxyvitamin D), and fibroblast growth factor 23 (FGF23) (Journal of Clinical Investigation, 2013). Key molecular components within these pathways, such as the calcium-sensing receptor (CaSR) and the RANK/RANKL/OPG signaling system, are critical for balancing bone resorption by osteoclasts and bone formation by osteoblasts (NIH, 2022). Dysregulation of these pathways leads to significant clinical conditions, including osteoporosis, hyperparathyroidism, and chronic kidney disease-mineral and bone disorder (CKD-MBD). Pharmacological interventions target specific nodes within these pathways to restore mineral balance or improve bone density; for example, bisphosphonates and denosumab inhibit bone loss, while anabolic agents like teriparatide and romosozumab stimulate new bone growth (Nature Reviews Endocrinology, 2020). Because this entry describes a broad physiological system rather than a single molecular target, it is classified as a pathway collection rather than an individual therapeutic target.

Other names

Calcium homeostasisBone mineral metabolismMineral homeostasis pathwaysCalcium-phosphate metabolism

Drugs targeting components of these pathways act through various mechanisms: calcimimetics (e.g., cinacalcet) allosterically activate the calcium-sensing receptor to reduce PTH; bisphosphonates and RANKL inhibitors (e.g., denosumab) reduce bone resorption by inhibiting osteoclast activity; PTH analogs (e.g., teriparatide) stimulate bone formation; and sclerostin inhibitors (e.g., romosozumab) promote osteoblast activity.